Natural killer group 2D receptor and its ligands in cancer immune escape

Shixin Duan(Central South University), Fuyan Wang(W. L. Gore & Associates (Germany)), Zuxing Xu(Central South University), Yunbo He(Central South University), Can Guo(Central South University), Zhaoyang Zeng(Gansu University of Traditional Chinese Medicine), Yongzhen Mo(Central South University), Guiyuan Li(Central South University), Yong Li(Baylor College of Medicine), Xiaoling Li(Southwestern Medical Center), Yian Wang(Central South University), Wei Xiong(Central South University), Fang Xiong(Central South University), Weihua Guo(Central South University), Chuting Liang(Central South University)
Molecular Cancer
February 27, 2019
10.1186/s12943-019-0956-8
Cited by 241

Related Papers

Neoantigen vaccine: an emerging tumor immunotherapy
|Molecular Cancer|2019|713
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|677
Effects of environmental pollutants on gut microbiota
|Environmental Pollution|2017|662
Regulatory mechanisms of PD-1/PD-L1 in cancers
|Molecular Cancer|2024|619
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|390